Anti-Human Abeta Recombinant Antibody (Ponezumab) (CAT#: TAB-227)

Recombinant monoclonal antibody to Abeta. Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.

Specific Inquiry
  • Size:

  • Conjugation:

  • Endotoxin:

  • Purity:

  • Formats:

  • Isotype Switching:

  • Fc Engineering:

  • Modalities:

Custom Production

We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.

Sequences:
Isotype :
Purity :
Endotoxin :
Quantity :
Conjugation :
Fc Engineering :
Modalities :
Other Requirements:
We require custom production
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Subcellular Location
Normal Tissue
RNA Expression

Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • IgG2 - kappa
  • Specificity
  • Tested positive against native human antigen.
  • Species Reactivity
  • Human
  • Applications
  • WB, ELISA, IP, FC, FuncS, Neut, IF
  • CAS
  • 1178862-65-1
  • Generic Name
  • Ponezumab
  • UNII
  • 1TG15H1XE9
  • MW
  • 148.3 kDa
  • Related Disease
  • Alzheimer's disease (AD)

Product Property

  • Purity
  • >95.0% as determined by analysis by RP-HPLC.
  • Storage
  • Store at -20°C for long-term storage. Store at 2-8°C for up to one month. Avoid freeze/thaw cycles.

Applications

  • Application Notes
  • The APP antibody has been reported in applications of IF, IHC, WB, Inhib.
    Inhibition: Approximately 24 h prior to measurements of vasodilatory responses animals were randomly administered 10 mg/kg i.p. ponezumab or an irrelevant IgG isotype control

Target

  • Alternative Names
  • Ponezumab;1178862-65-1;PF-04360365;RN-1219;RN1219;9TL;Ab2;APP;amyloid beta (A4) precursor protein;AD1, Alzheimer disease;amyloid beta A4 protein;peptidase nexin II;preA4;protease nexin-II;peptidase nexin-II;beta-amyloid peptide;alzheimer disease amyloid p

Related Resources

  • Biosimilar Overview
Please refer to Ponezumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Ponezumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Ponezumab"

Afuco™ Anti-APP ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-227)
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Abeta. It is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.

See other products for "APP"

Select a product category from the dropdown menu below to view related products.
Please select product type
Mouse Antibody Products Single Domain Antibody Products Chimeric Antibody Products Human Antibody Products Humanized Antibody Products Chicken IgY Antibody Products Rabbit Monoclonal Antibody Products Epitope-Specific Antibody Products Neuroscience Antibody Products IgG Antibody Products Fab Antibody Products ScFv Antibody Products ADCC Enhanced Antibody Products IgM Antibody Products Antibody Magnetic Beads Non-Human Primate (NHP) Antibody Products ScFv-Fc Chimera Products Extracellular Vesicle (EV) Antibody Products

Customer Reviews and Q&As

Submit a review or a question

There are currently no Customer reviews or questions for TAB-227. Click the button above to contact us or submit your feedback about this product.

Popular products with customers


For Research Use Only. Not For Clinical Use.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Go to compare

Go to compare